Skip to content
OpenCapital
Get started

Aclaris Therapeutics ACRS Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Incyte logo
IncyteINCY
——

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%—

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0×0.0×
Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Aclaris Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's contingent consideration fair value adjustments?
Aclaris Therapeutics (ACRS) reported contingent consideration fair value adjustments of $400K in Q4 2025.
What is the long-term trend for Aclaris Therapeutics's contingent consideration fair value adjustments?
Over 3 years (2021 to 2025), Aclaris Therapeutics's contingent consideration fair value adjustments has grown at a -54.5% compound annual growth rate (CAGR), from $24.34M to $2.3M.